AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01920009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist counselling session with a motivational interview
Description: The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication
Study NCT02710734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study NCT02710734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study NCT04338984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
Study NCT03289455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO3 (CD19/22 CAR T cells
Description: Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
Study NCT03888911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose IQP-LU-104 (5120mg)
Description: 1 sachet to be taken 2 times daily orally, together with 2 main meals
Study NCT03888911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose IQP-LU-104 (2560mg)
Description: 1 sachet to be taken 2 times daily orally, together with 2 main meals
Study NCT03888911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet to be taken 2 times daily orally, together with 2 main meals
Study NCT02919085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early ambulation
Description: Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
Study NCT02138513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
Study NCT04338984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia.~Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%.
Study NCT00488280 — intervention group
Intervention type: BEHAVIORAL
Intervention: Locomotor Training
Description: Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
Study NCT03370614 — intervention group
Intervention type: OTHER
Intervention: IBS Group
Description: Participants will receive approximately 2 months of dietary and nutritional counseling.
Study NCT03370614 — intervention group
Intervention type: OTHER
Intervention: Healthy Control Group
Description: Participants will not receive any dietary or nutritional counseling.
Study NCT04216160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACN cream (YUN)
Description: Application of the facial cream ACN (YUN) twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
Study NCT04216160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cream (YUN)
Description: Application of the facial placebo cream twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
Study NCT02185664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: landmark technique
Description: The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
Study NCT02185664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static Ultrasound technique
Description: Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
Study NCT03710876 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rAd-IFN
Description: Adenovirus-Delivered Interferon Alpha-2b
Study NCT03710876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib Oral Product
Description: 400 mg twice daily
Study NCT03196479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and propofol mixture with 1:6 ratio
Description: K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
Study NCT02429609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moorfields Acuity Chart
Study NCT03710876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib Oral Product
Description: 400 mg twice daily
Study NCT04252820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WarmTouch total body blanket, Covidien Ltd, Mansfield, USA
Description: Forced-air warming will be applied in the preanesthetic room
Study NCT00601965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20 mg daily oral escitalopram
Study NCT00601965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 20 mg daily oral escitalopram
Study NCT00601965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill of daily oral escitalopram
Study NCT00601965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: 16 weekly 1-hour sessions
Study NCT00601965 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: 16 weekly 1-hour sessions
Study NCT02042443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT02042443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02042443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02042443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02042443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT02882503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound - radiofrequency ablation (EUS-RFA)
Description: Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
Study NCT03341026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metronom CGM device
Description: Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
Study NCT03341026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metronom CGM device
Description: Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
Study NCT03000712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml
Description: biological : Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml drug: saline solution
Study NCT00740272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation + pacemaker implantation
Description: regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
Study NCT03710876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
Study NCT00740272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Description: regular pacemaker implantation
Study NCT03957980 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Occupational therapy
Description: Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
Study NCT00555581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
Study NCT03057561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)
Description: Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
Study NCT03057561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with contrast agent, Gadovist
Description: Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
Study NCT04083183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
Description: Given IV
Study NCT04083183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04083183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04083183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV
Study NCT04083183 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04083183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo hematopoietic cell transplantation
Study NCT04083183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO or IV
Study NCT04083183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT04083183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT04083183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01197885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMAB362
Description: Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
Study NCT03710876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
Study NCT02710734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Description: 2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
Study NCT02710734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder tumor
Description: Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
Study NCT03409068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: C2-C4 compartment anesthetic block
Description: C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
Study NCT03409068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Costagliola block
Description: Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
Study NCT00181623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Prolactin
Study NCT01137318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation and Parent Training
Description: Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
Study NCT01137318 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive remediation and Parent Training
Description: Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
Study NCT04622982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)
Description: Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) \<30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist.
Study NCT03196479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and propofol mixture with 1:4 ratio
Description: K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
Study NCT02965313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SSLS Procedure
Description: Synthetic suture repair
Study NCT02965313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BSSVF-M Procedure
Description: Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
Study NCT04043247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
Study NCT04043247 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS without electrical stimulation
Description: Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
Study NCT04210102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lung Ultrasound (LUS)
Description: Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs.
Study NCT03036306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCX-001
Description: Nefopam cream formulation
Study NCT03036306 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cream formulation without Nefopam
Study NCT00982124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
Study NCT04544540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Units of transfusion
Description: Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
Study NCT02809911 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Provant
Study NCT00589862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavix (Clopidogrel)
Description: 150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
Study NCT04242394 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP
Description: Routine ERCP procedures with gallbladder in situ patient
Study NCT02221479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor GZ316455
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study NCT02221479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study NCT02221479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study NCT03057509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-DOTA-TOC
Description: Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
Study NCT03057509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens PET/MR scanner
Description: Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
Study NCT03057509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Siemens Software
Description: The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
Study NCT03057509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAR Octreotide
Description: LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
Study NCT02710734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
Study NCT02710734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Intravenous on day 1 with radiation treatment
Study NCT02055027 — intervention group
Intervention type: OTHER
Intervention: Comparison between groups
Description: Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
Study NCT01284322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients